<DOC>
	<DOC>NCT01780987</DOC>
	<brief_summary>The purpose of this study is to investigate safety of apixaban in Japanese acute DVT/PE subjects when symptomatic DVT/PE subjects are treated with 10 mg BID apixaban for 7 days as initial therapy followed by 5 mg BID apixaban for 23 weeks as long-term therapy (total treatment period is 24 weeks)</brief_summary>
	<brief_title>AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Acute symptomatic proximal DVT with evidence of proximal thrombosis Acute symptomatic PE with evidence of thrombosis in segmental or more proximal branches Active bleeding or high risk for bleeding contraindicating treatment with UFH and a VKA. Uncontrolled hypertension: systolic blood pressure &gt; 180 mm Hg or diastolic blood pressure &gt; 110 mm Hg Subjects requiring dual antiplatelet therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>DVT</keyword>
	<keyword>PE</keyword>
	<keyword>VTE</keyword>
</DOC>